Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis

BACKGROUND: Etelcalcetide is an intravenous calcimimetic approved for treatment of secondary hyperparathyroidism (sHPT) in patients receiving hemodialysis. Besides lowering parathyroid hormone (PTH), etelcalcetide also significantly reduces fibroblast growth factor 23 (FGF23), but the mechanisms are...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Kidney J
Main Authors: Wolf, Myles, Block, Geoffrey A, Chertow, Glenn M, Cooper, Kerry, Fouqueray, Bruno, Moe, Sharon M, Sun, Yan, Tomlin, Holly, Vervloet, Marc, Oberbauer, Rainer
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2019
Fag:
CKD-Mdb
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7025329/
https://ncbi.nlm.nih.gov/pubmed/32082556
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfz034
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker